

# **PSP-QoL**

# Category

**Healthcare Tools** 

# PSP-QoL is a Quality of Life instrument for people with progressive supranuclear palsy

The Health-Related Quality of Life questionnaire for Patients with Progressive Supranuclear Palsy

PSP-QoL is a Quality of Life instrument for people with progressive supranuclear palsy.

#### Description

Progressive supranuclear palsy (PSP) is a rare and progressive condition that can cause problems with balance, movement, vision, speech and swallowing.

It's caused by increasing numbers of brain cells becoming damaged over time. The PSP Association estimates there are around 4,000 people with PSP living in the UK. However, it's thought that the true figure could be much higher, because many cases may be misdiagnosed. Most cases of PSP develop in people who are over 60 years of age.

PSP-QoL is a patient-reported outcome measure for progressive supranuclear palsy (PSP). The Supranuclear Palsy Quality of Life scale (PSP-QoL) may be a helpful patient-reported scale for clinical trials and studies in PSP.

Please note that **translated versions of PSP-QoL** are available for purchase. For more details, please contact us via the "Contact us" section.

## Placing an order on XIP

To license this product, please select the **appropriate licence option** on the right-hand side of this page. Terms can be previewed from the "Preview terms" link.

To place an order, please locate the <u>Sign-in</u> or <u>Register</u> options on the top right side of this page. You can either sign in to your existing account or register for a new now. **Please note that your account should be created using your academic/ institutional e-mail address.** 

Before completing an order and accessing the material, each order requires prior authorization, with processing times varying depending on the product.

For additional guidance on how to create an account and place an order, refer to the FAQs.

## References

 Hobart, Burn, Bower, Poon, Lang, Litvan, Lees, Quinn, Selai, Schrag(July 2006), http://http://?dx.?doi.?org/?10.?1212/?01.?wnl.?0000223826.?84080.?97, http://www.neurology.org/, 39-44